Page last updated: 2024-08-03 02:37:59
resolvin d5
Description
resolvin D5: isolated from E coli; structure in first source [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 16061139 |
| SCHEMBL ID | 12698945 |
| CHEBI ID | 138645 |
| MeSH ID | M0574409 |
Synonyms (12)
| Synonym |
|---|
| resolvin d5 |
| (5z,7s,8e,10z,13z,15z,17s,19z)-7,17-dihydroxydocosahexaenoic acid |
| 7s,17s-dihydroxy-5z,8e,10z,13z,15e,19z-docosahexaenoic acid |
| (5z,7s,8e,10z,13z,15z,17s,19z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoic acid |
| CHEBI:138645 |
| SCHEMBL12698945 |
| LMFA04030003 |
| 7s,17s-dihydroxy-docosa-5z,8e,10z,13z,15e,19z-hexaenoic acid |
| 7s,17s-dihydroxy-docosa-5z,8e,10z,13z,15e,19z-hexaenoate |
| rvd5 |
| Q59864199 |
| (5z,7s,8e,10z,13z,15e,17s,19z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoic acid |
Pathways (6)
resolvin d5 is involved in 6 pathway(s), involving a total of 2024 unique proteins and 1785 unique compounds
Research
Studies (20)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 11 (55.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (4.76%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (4.76%) | 0.25% |
| Other | 19 (90.48%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| vancomycin | | glycopeptide | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glucose, (beta-d)-isomer | | D-glucopyranose | epitope;
mouse metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fibrinogen | | iditol | fungal metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2018 | 2022 | 3.7 | medium | 1 | 0 | 0 | 0 | 1 | 2 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| leukotriene b4 | | dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid | human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 18-hydroxy-5,8,11,14-eicosatetraenoic acid | | | | 2022 | 2022 | 2.0 | medium | 1 | 0 | 0 | 0 | 0 | 1 |
| 5s,12r,18r-trihydroxy-6z,8e,10e,14z,16e-eicosapentaenoic acid | | hydroxy polyunsaturated fatty acid;
long-chain fatty acid;
nonclassic icosanoid;
resolvin;
triol | anti-inflammatory agent;
human xenobiotic metabolite | 2021 | 2022 | 2.5 | low | 1 | 0 | 0 | 0 | 0 | 2 |
| resolvin d2 | | hydroxy polyunsaturated fatty acid;
resolvin;
secondary allylic alcohol;
triol | anti-inflammatory agent;
anti-obesity agent;
estrogen receptor agonist;
human xenobiotic metabolite;
rat metabolite | 2021 | 2022 | 2.5 | medium | 1 | 0 | 0 | 0 | 0 | 2 |
| protectin d1 | | dihydroxydocosahexaenoic acid;
protectin;
secondary allylic alcohol | anti-inflammatory agent;
apoptosis inhibitor;
hepatoprotective agent;
human xenobiotic metabolite;
neuroprotective agent;
PPARgamma agonist;
specialised pro-resolving mediator | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| resolvin e2 | | diol;
hydroxy polyunsaturated fatty acid;
resolvin;
secondary allylic alcohol | anti-inflammatory agent;
human xenobiotic metabolite;
rat metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| resolvin d1 | | hydroxy polyunsaturated fatty acid;
resolvin;
triol | anti-inflammatory agent | 2012 | 2022 | 6.0 | high | 1 | 0 | 0 | 0 | 4 | 2 |
| resolvin D4 | | hydroxy polyunsaturated fatty acid;
resolvin;
secondary allylic alcohol;
triol | anti-inflammatory agent;
human xenobiotic metabolite | 2022 | 2022 | 2.0 | medium | 1 | 0 | 0 | 0 | 0 | 1 |
| resolvin d3 | | hydroxy polyunsaturated fatty acid;
resolvin;
secondary allylic alcohol;
triol | anti-inflammatory agent;
human xenobiotic metabolite | 2022 | 2022 | 2.0 | medium | 1 | 0 | 0 | 0 | 0 | 1 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Adjuvant Arthritis | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Allergic Reaction | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Allodynia | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| American Trypanosomiasis | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anxiety | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Arthritis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arthritis, Rheumatoid | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Autoimmune Diabetes | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Blood Poisoning | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Pancreas | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Carcinoma, Ductal, Pancreatic | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Carcinoma, Pancreatic Ductal | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cardiovascular Stroke | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chagas Disease | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Pain | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Colitis | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colitis, Mucous | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Craniofacial Pain | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cronobacter Infections | 0 | | 2017 | 2021 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Depression | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Dermatoses | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetes Mellitus, Type 1 | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Diarrhea | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Disease Models, Animal | 0 | | 2017 | 2023 | 3.2 | low | 0 | 0 | 0 | 0 | 1 | 3 |
| Diseases of Immune System | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| E coli Infections | 0 | | 2012 | 2020 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Endotoxin Shock | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Enterobacteriaceae Infections | 0 | | 2017 | 2021 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Escherichia coli Infections | 0 | | 2012 | 2020 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Facial Pain | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Heart Disease, Ischemic | 0 | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Hypersensitivity | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypothermia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypothermia, Accidental | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Immune System Diseases | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Staphylococcal | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Inflammation | 0 | | 2018 | 2023 | 3.7 | low | 0 | 0 | 0 | 0 | 3 | 3 |
| Innate Inflammatory Response | 0 | | 2018 | 2023 | 3.7 | low | 0 | 0 | 0 | 0 | 3 | 3 |
| Invasiveness, Neoplasm | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Irritable Bowel Syndrome | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Myocardial Infarction | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myocardial Ischemia | 0 | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Pain, Chronic | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Pancreatic Neoplasms | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Peritonitis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Polyarthritis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Primary Peritonitis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Recrudescence | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Rheumatoid Arthritis | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Sepsis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Shock, Septic | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Skin Diseases | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Staphylococcal Infections | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis.Scientific reports, , 08-27, Volume: 11, Issue:1, 2021
Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis.JCI insight, , 07-11, Volume: 4, Issue:13, 2019
GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections.The Journal of clinical investigation, , 01-02, Volume: 130, Issue:1, 2020
Infection regulates pro-resolving mediators that lower antibiotic requirements.Nature, , Apr-25, Volume: 484, Issue:7395, 2012
Efficient biotransformation of docosahexaenoic acid-rich oils into the lipid mediator resolvin D5 by cells expressing 15S-lipoxygenase using a bioreactor.Bioresource technology, , Volume: 388, 2023
Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS.Gut, , Volume: 70, Issue:7, 2021
Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis.Scientific reports, , 08-27, Volume: 11, Issue:1, 2021
Resolvin D5, a Lipid Mediator, Inhibits Production of Interleukin-6 and CCL5 Via the ERK-NF-κB Signaling Pathway in Lipopolysaccharide-Stimulated THP-1 Cells.Journal of microbiology and biotechnology, , Jan-28, Volume: 30, Issue:1, 2020
Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5.Science advances, , Volume: 5, Issue:11, 2019
Comprehensive targeted and non-targeted lipidomics analyses in failing and non-failing heart.Analytical and bioanalytical chemistry, , Volume: 410, Issue:7, 2018
Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis.Scientific reports, , 08-27, Volume: 11, Issue:1, 2021
Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis.JCI insight, , 07-11, Volume: 4, Issue:13, 2019
Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis.Scientific reports, , 08-27, Volume: 11, Issue:1, 2021
Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis.JCI insight, , 07-11, Volume: 4, Issue:13, 2019
Sex Dimorphism in Resolvin D5-induced Analgesia in Rat Models of Trigeminal Pain.The journal of pain, , Volume: 24, Issue:5, 2023
Resolvin D5 disrupts anxious- and depressive-like behaviors in a type 1 diabetes mellitus animal model.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 395, Issue:10, 2022
Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS.Gut, , Volume: 70, Issue:7, 2021
Specialized Proresolving Mediators Rescue Infant Mice from Lethal Citrobacter rodentium Infection and Promote Immunity against Reinfection.Infection and immunity, , Volume: 85, Issue:10, 2017
GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections.The Journal of clinical investigation, , 01-02, Volume: 130, Issue:1, 2020
Infection regulates pro-resolving mediators that lower antibiotic requirements.Nature, , Apr-25, Volume: 484, Issue:7395, 2012
Efficient biotransformation of docosahexaenoic acid-rich oils into the lipid mediator resolvin D5 by cells expressing 15S-lipoxygenase using a bioreactor.Bioresource technology, , Volume: 388, 2023
Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS.Gut, , Volume: 70, Issue:7, 2021
Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis.Scientific reports, , 08-27, Volume: 11, Issue:1, 2021
Resolvin D5, a Lipid Mediator, Inhibits Production of Interleukin-6 and CCL5 Via the ERK-NF-κB Signaling Pathway in Lipopolysaccharide-Stimulated THP-1 Cells.Journal of microbiology and biotechnology, , Jan-28, Volume: 30, Issue:1, 2020
Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5.Science advances, , Volume: 5, Issue:11, 2019
Comprehensive targeted and non-targeted lipidomics analyses in failing and non-failing heart.Analytical and bioanalytical chemistry, , Volume: 410, Issue:7, 2018